Hansmann M L, Wacker H H, Gralla J, Lumbeck H, Kossmahl M, Heidebrecht H J, Radzun H J, Parwaresch M R
Department of Pathology, Christian Albrechts University, Kiel, Germany.
Blood. 1991 Feb 15;77(4):809-17.
In the search for immunoreagents appropriate for the histopathologic diagnosis of malignant B-cell lymphomas in routinely processed paraffin sections, a new monoclonal antibody, Ki-B5, was generated using a high-grade B-cell lymphoma as the immunogene. Ki-B5 is a mouse IgG1/kappa that recognizes five protein fractions of about 84, 82, 55, 48, and 27 Kd after biosynthetic radiolabeling and immunoprecipitation. Protein fractions with the molecular weights of approximately 84 and 82 Kd were expressed on the cell surface and show that Ki-B5 is probably unrelated to CD45. It was possible through electron microscopy to visualize the membrane-bound portion of Ki-B5. Extensive immunohistologic studies on normal human tissue and various neoplasias demonstrated the high specificity of Ki-B5 to normal human B cells and a minor subgroup of plasma cells. Except for ML-2, which is a myelomonocytic human cell line, Ki-B5 exclusively recognized the B-cell lineage, including EB-3, BALL-1, and NALM-1. All carcinomas, sarcomas, and malignant melanomas tested with Ki-B5 were negative. Although normal granulocytes and monocytes were constantly negative, three of eight myelomonocytic leukemias coreacted with this antibody. Eight of the 57 T-cell lymphomas studied were positive to Ki-B5. Five were classified as lymphoblastic, two represented T8-CLL, and one was classified as immunoblastic T-cell lymphoma. Only 3 of 126 cases of B-cell lymphoma, including rare types not considered in the current classifications, were negative to Ki-B5. Plasmacytomas were also negative, except for one case. Irrespective of the cases of lymphoblastic lymphoma and plasmacytoma, Ki-B5 represents a new monoclonal antibody appropriate for the diagnosis and immunophenotyping of malignant lymphomas in routinely processed paraffin sections.
为了寻找适用于常规处理石蜡切片中恶性B细胞淋巴瘤组织病理学诊断的免疫试剂，以一种高级别B细胞淋巴瘤作为免疫原，制备了一种新的单克隆抗体Ki-B5。Ki-B5是一种小鼠IgG1/κ，在生物合成放射性标记和免疫沉淀后，可识别约84、82、55、48和27 Kd的五个蛋白组分。分子量约为84和82 Kd的蛋白组分在细胞表面表达，表明Ki-B5可能与CD45无关。通过电子显微镜可以观察到Ki-B5的膜结合部分。对正常人体组织和各种肿瘤进行的广泛免疫组织学研究表明，Ki-B5对正常人体B细胞和一小部分浆细胞具有高度特异性。除了人骨髓单核细胞系ML-2外，Ki-B5仅识别B细胞谱系，包括EB-3、BALL-1和NALM-1。用Ki-B5检测的所有癌、肉瘤和恶性黑色素瘤均为阴性。虽然正常粒细胞和单核细胞始终为阴性，但8例骨髓单核细胞白血病中有3例与该抗体发生共反应。在研究的57例T细胞淋巴瘤中，有8例对Ki-B5呈阳性。其中5例为淋巴母细胞性，2例为T8-CLL，1例为免疫母细胞性T细胞淋巴瘤。在126例B细胞淋巴瘤病例中，包括当前分类中未考虑的罕见类型，只有3例对Ki-B5呈阴性。浆细胞瘤也为阴性，但有1例除外。不考虑淋巴母细胞淋巴瘤和浆细胞瘤病例，Ki-B5是一种适用于常规处理石蜡切片中恶性淋巴瘤诊断和免疫表型分析的新单克隆抗体。
